Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study). Materials and Methods Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients. Results More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child- Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatment-emergent adverse events was similar in both Child-Pugh A (85.4%) and Child-Pugh B (84.8%) patients. Conclusion Sorafenib was well tolerated by Korean HCC patients in clinical settings, and the safety profile did not appear to differ by Child-Pugh status. Survival benefit in Korean patients was in line with that of a previous pivotal phase III trial (SHARP).
Abstract
Purpose The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study). Materials and Methods Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients. Results More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child- Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatment-emergent adverse events was similar in both Child-Pugh A (85.4%) and Child-Pugh B (84.8%) patients. Conclusion Sorafenib was well tolerated by Korean HCC patients in clinical settings, and the safety profile did not appear to differ by Child-Pugh status. Survival benefit in Korean patients was in line with that of a previous pivotal phase III trial (SHARP).
참고문헌 (16)
- Kim DY, "Epidemiology and surveillance of hepatocellular carcinoma", Liver Cancer, 1, pp.2~14 (2012)
- Ferlay J, "Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008", Int J Cancer, 127, pp.2893~2917 (2010)
- Bolondi L, "Heterogeneity of patients with intermediate(BCLC B)hepatocellular carcinoma : proposal for a subclassification to facilitate treatment decisions", Semin Liver Dis, 32, pp.348~359 (2012)
- Jeng KS, "Heterogeneity of hepatocellular carcinoma contributes to cancer progression", Crit Rev Oncol Hematol, 94, pp.337~347 (2015)
- Han KH, "Survival of hepatocellular carcinoma patients may be impro-ved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study", J Clin Gastroenterol, 47, pp.538~544 (2013)
- Santi V, "The changing scenario of hepatocellular carcinoma over the last two decades in Italy", J Hepatol, 56, pp.397~405 (2012)
- European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer, "EASLEORTC clinical practice guidelines : management of hepato-cellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- "National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: hepatobiliary cancers (version 2.2013)" (2012)[URL]
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol", Lancet Oncol, 10, pp.25~34 (2009)
- Lencioni R, "GIDEON(Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) : second interim analysis", Int J Clin Pract, 68, pp.609~617 (2014)
- Lencioni R, "Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib(GIDEON)study", Int J Clin Pract, 64, pp.1034~1041 (2010)
- ) in > 3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction, "J Clin Oncol", 2013, 4126~
- Abou-Alfa GK, "Phase II study of sorafenib in patients with advanced hepatocellular carcinoma", J Clin Oncol, 24, pp.4293~4300 (2006)
- and of its treatment with sorafenib): subgroup analysis by initial sorafenib (Sor) dose, "Hepatology", 2011, 1389~
- Bruix J, "American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)